利用中美冠科数据库,快速查找所需模型
OncoExpress|HuBase|XenoBase|MuBase

白皮书

中美冠科生物通过协助生物制药公司解决当今肿瘤学和心血管与代谢疾病中最紧迫的问题为世界药物研发带来曙光。

Use our Whitepapers to Expand Your Knowledge

These top level issues are discussed in our White Papers, leveraging our industry expertise to help customers answer the most challenging preclinical research questions.

CVMD

Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

The biggest challenge in modeling human diabetes in animal models is a lack of translatable platforms fully capturing all aspects of this progressive condition including polygenic disease, pre-diabetic state, and complications. New translational platforms are required that model multiple aspects of human disease, and can be used to develop agents that control more than one diabetes risk factor. Read our White Paper to learn about the development of highly translatable rodent and NHP models, more closely mirroring human disease development for more predictive preclinical study.

Oncology

How to Choose the Correct I/O Model

With the continued rise of immunotherapeutics, more preclinical research is moving towards using immunocompentent models, which are required to assess immunomodulatory agents. Choosing the correct model from the variety available can be difficult, but is needed to help to efficiently progress novel agents. Download our White Paper to learn which human specific and mouse analogue models are available, and how to select the best model for any given immuno-oncology study.

How to Use CrownBio’s Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Target identification and MOA studies are a vital early stage in cancer drug development, and require disease-relevant cell-based platforms, with linked later stage models to accelerate lead compounds. Discover how CrownBio’s integrated oncology portfolio of in vitro, in vivo, and ex vivo products and services help advance target identification and MOA studies within drug discovery programs, allowing go/no-go decisions to be made with confidence.

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Human tumor bearing humanized mouse models are needed for the preclinical assessment of human-specific immunotherapeutics. Given the complexity of these models (including hCD34+ and hPBMC mice combined with PDX and traditional xenografts), the key to optimizing their use is to bring together an in depth knowledge of each model features and limitations, with bespoke study designs, centred around the specific question being asked in each study. Download our White Paper to discover different immune system humanization strategies and how these result in models with differing pros and cons, alongside successful model utilization in cancer pharmacology case studies.

精准分析

肿瘤药物研究目前为改进新药研发效率和性价比,急需解决过高的新药晚期临床实验失败率问题。利用人源肿瘤异体移植模型(PDX)这一目前最具预测性的临床前实验模型进行精准分析,能够鉴定可以用于以对治疗的敏感度进行患者成层的分子生物标记物或基因签名,从而降低药物研发失败率。让中美冠科生物的精准分析白皮书帮助您在临床前了解哪些患者更能从您的治疗中获益。

The Ultimate Guide to Mouse Clinical Trials

New approaches are needed in oncology, to better predict clinical efficacy within preclinical assessment. Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a highly predictive alternative to traditional drug discovery methods, providing a more clinically relevant situation, a better perspective of patient-to-patient heterogeneity, and a framework for biomarker discovery. Download our White Paper to discover the various types of MCT, and identify which method will best progress any given drug development program.

关注微信公众号